Company news

Janux Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

December 26, 2022

Janux Therapeutics to Present at Upcoming Investor Conferences in November

November 21, 2022

Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

November 9, 2022

Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

October 11, 2022

Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources

September 22, 2022

Janux Therapeutics Appoints Winston Kung to Board of Directors

September 21, 2022

Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September

August 30, 2022

Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

August 8, 2022

Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference

June 1, 2022

Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer

May 30, 2022

Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

May 9, 2022

Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr

April 25, 2022

Janux Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

March 17, 2022

Janux Therapeutics to Present at Upcoming March Investor Conferences

February 28, 2022

Janux Therapeutics Appoints Byron Robinson, Ph.D., J.D., as Chief Strategy Officer

February 28, 2022

Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference

January 4, 2022

Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results

November 8, 2021

Janux Therapeutics to Present Virtually at Upcoming Investor Conferences

November 7, 2021

Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors

September 8, 2021

Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference

September 6, 2021

Janux Therapeutics Reports Second Quarter 2021 Financial Results

August 9, 2021

Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer

July 18, 2021

Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

June 14, 2021

← Newer news releases

Decks

The 5 newest of 7 decks. Every deck is listed under its year.